Advertisement
Advertisement

Agnes Shanley

UBM Americas

Agnes Shanley is senior editor of Pharmaceutical Technology.

Articles

Advertisement

Recovering the Value of Repurposed Drugs

August 01, 2015

Currently, pharma has only scratched the surface of the potential value of repurposing drugs, says consultant Hermann Mucke. Contract service partners are playing a more prominent role, but could play an even larger one in these efforts.

Needle in the Haystack, or Rembrandt in the Attic? Drug Repurposing's New Strategy

July 31, 2015

Competitive pressures are driving more companies to repurpose APIs that had originally been developed for other indications. The industry has only "scratched the surface" of what might be possible, says consultant Hermann Mucke

Understanding the Extent of the Counterfeit and Substandard Drug Problem

July 14, 2015

Important research is under way that will help us understand the extent of the presence of substandard, adulterated and counterfeit drugs around the world, and, thus, strengthen enforcement efforts and public outreach programs. Future studies will focus on the API and overall chemical content

Advertisement
Advertisement
Advertisement
Advertisement
x